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Introduction: There is growing evidence that virtual reality (VR) can be used in the treatment of chronic pain 2 
conditions. However, further research is required in order to better understand the analgesic mechanisms 3 
during sensitised pain states. 4 
Objectives: We examined the effects of an immersive polar VR environment on capsaicin-induced ongoing pain 5 
and secondary hyperalgesia. We also investigated whether the degree of analgesia was related to baseline 6 
conditioned pain modulation (CPM) responses.  7 
Methods: Nineteen subjects had baseline CPM and electrical pain perception (EPP) thresholds measured prior 8 
to the topical application of capsaicin cream. Visual analogue scale (VAS) ratings were measured to track the 9 
development of an ongoing pain state and EPP thresholds were used to measure secondary hyperalgesia. The 10 
effects of a passive polar VR environment on ongoing pain and secondary hyperalgesia were compared to sham 11 
VR (i.e. 2D monitor screen) in responders to capsaicin (n=15).   12 
Results: VR was associated with a transient reduction in ongoing pain and an increase in EPP thresholds in an 13 
area of secondary hyperalgesia. Baseline CPM measurements showed a significant correlation with VR-induced 14 
changes in secondary hyperalgesia, but not with VR-induced changes in ongoing pain perception. There was no 15 
correlation between VR-induced changes in pain perception and VR-induced changes in secondary 16 
hyperalgesia.  17 
Conclusions: Virtual reality can reduce the perception of capsaicin-induced ongoing pain perception and 18 
secondary hyperalgesia. We also show that CPM may provide a means by which to identify individuals likely to 19 
respond to VR therapy.   20 




Virtual reality (VR) interventions have shown promise as a novel distraction-based analgesic therapy for use in 2 
painful medical procedures [5; 10; 12; 13] and during acute pain states [15; 16; 33]. There is now a growing 3 
body of evidence that suggests VR can be used in the management of chronic pain conditions [21-23; 35; 38; 4 
45] and visual distraction is a key component of cognitive behavioural therapy [24]. However, there has been 5 
limited investigation into the analgesic mechanisms of VR stimulation during sensitised pain states.  6 
Distraction-based analgesia is a form of non-pharmacological therapy that has been shown to alter the 7 
perception of acute pain by reducing the activity within pain-related brain regions [1; 15]. The use of an 8 
immersive virtual environment has been shown to be effective at reducing the perception of pain during dental 9 
procedures which normally require local anaesthesia [5]. The use of VR in distraction analgesia has also shown 10 
clinical utility during wound debridement associated with severe to excruciating pain in burn patients [10; 13]. 11 
Interestingly, recent advances have shown that it is possible to predict the efficacy of VR in acute experimental 12 
pain conditions by measuring the efficiency of endogenous pain inhibitory pathways using the conditioned pain 13 
modulation (CPM) paradigm [3].  14 
Attempts to apply immersive VR environments to chronic or ongoing pain conditions are still very much their 15 
infancy [23]. The majority of studies to date have typically involved measuring changes in pain perception (i.e. 16 
pain scores) in groups of patients with mixed aetiologies [21; 22; 45]. However, there is a distinct lack of research 17 
into whether VR can reduce altered nociceptive processing associated with the development of sensitised pain 18 
states (i.e. central sensitisation [46]). The capsaicin model can be used to measure distinct chronic pain features 19 
in healthy volunteers, including spinal representations of secondary hyperalgesia and ongoing pain sensitivity 20 
[8; 30]. It provides a means by which to determine the analgesic mechanisms associated with immersion within 21 
a VR environment and may shed light on the future clinical utility of VR as a novel analgesic therapy in the 22 
treatment of chronic pain conditions.   23 
These lines of evidence have led us to examine the analgesic mechanisms of an immersive VR environment 24 
during an experimentally induced sensitised pain state by measuring the effects on capsaicin-induced ongoing 25 
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pain perception and secondary hyperalgesia in healthy volunteers. We also wanted to determine whether the 1 
efficiency of CPM measured at baseline could be used to identify individuals who were more likely to have a 2 
stronger analgesic response to VR following the onset of capsaicin-induced pain sensitivity.  3 
Materials and methods  4 
Subject screening and recruitment   5 
All procedures were approved by the Imperial College Research Ethics Committee (18IC4435). All participants 6 
were informed of the experimental protocols and subsequently provided written consent in accordance with 7 
the principles of the declaration of Helsinki. All subjects were recruited from Imperial College London and were 8 
initially screened to see if they met any of the exclusion criteria for pain testing (i.e. pregnancy, diabetes, blood 9 
disorders, neurological conditions, immune-suppression, inflammatory disease, psychiatric conditions, taking 10 
steroid, antibiotic or pain medicines). Following initial screening, 19 healthy subjects (mean age: 24.74 ± 0.33; 11 
10 females) participated in the study. According to their pain response to application of topical capsaicin cream, 12 
15 subjects (mean age: 25.2 ± 0.47; 8 females) were defined as responders (i.e. A maintained pain intensity 13 
rating >50 rating on a modified visual analogue scale (VAS) and a drop in pain threshold in an area of secondary 14 
hyperalgesia [8; 28; 42]) and 4 subjects (mean age: 23 ± 0.35; 2 females) were defined as non-responders.  15 
Experimental design and protocol 16 
Using a within-subject design, the effects of VR and sham VR stimulation on capsaicin-induced ongoing pain 17 
perception and secondary hyperalgesia were investigated in a randomised manner (Figure 1). Baseline CPM 18 
responses were also examined (i.e. in the absence of capsaicin).  19 
CPM: Pressure pain thresholds (PPT; test stimulus) were first determined by applying 3 continuous ramps of 20 
increasing intensity (0.5 kg/s) on the dominant volar forearm using a pressure algometer (WAGNER® FDN 100; 21 
contact area 1 cm2). After a 15-minute rest, participants were instructed to immerse the non-dominant hand in 22 
ice cold water (maintained at 8 degrees Celsius) up to the wrist and palm-side down for 2 minutes (i.e. the cold 23 
pressor test; conditioning stimulus). Participants were asked to rate pain perception every 10 seconds on a 24 
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conventional VAS from 0  - 100 (0 = no pain; 10-30 = mild pain; 40-60 = moderate pain; 70-90 = severe pain; 1 
100 = worst pain imaginable). PPTs (i.e. test stimulus) were then immediately determined by re-applying 3 2 
continuous ramps of increasing intensity (0.5 kg/s) to the dominant forearm [37; 48].  3 
Baseline electrical pain perception (EPP) threshold testing: Following a 15 minute CPM wash-out period [25], 4 
Participants were then familiarized with the EPP threshold testing. Each transcutaneous electrical stimulus 5 
consisted of a standard, constant-current 1-ms duration square pulse using a constant current stimulator (DS7A, 6 
Digitimer, UK) [20]. An area on the left L5 dermatome, one third the way along a line from the left lateral femoral 7 
epicondyle to the left lateral malleolus was marked with a non-permanent marker and a measurement map 8 
was drawn using four 4.5cm spokes from the central point in proximal, distal, medial and lateral directions. 4 9 
modified Ag/AgCl electrodes (self-adhesive, 1 cm diameter, CareFusion, UK) were then positioned around each 10 
of the 4 points (Figure 1A). Pain thresholds (mA) were then determined at each of the 4 points by increasing 11 
the current intensity in 0.5 mA steps at 1 Hz and was defined as the mean of 3 intensities logged as the point at 12 
which sensation transitioned from being a ‘’heavy tapping’’ sensation (i.e. no pain) to a sharp ‘’pinprick’’ pain 13 
[20]. 14 
Capsaicin pain model: All Participants then received topical application of capsaicin cream (1% w/w, 15 
Pharmacierge, London, UK). Using a 1 ml syringe, 50 µl was ejected onto a 9 mm diameter clear plastic disc 16 
which was then placed face-down in the centre of the measurement map, remaining in place for the remainder 17 
of the protocol (area of capsaicin skin contact: 64 mm2) [8]. The participants used a modified VAS used 18 
previously [8] where 0 = no sensation; 50 = pain threshold; 100 = worst pain imaginable. Following application 19 
of capsaicin cream, the participants were instructed to rate the sensation every 3 minutes for 120 minutes. The 20 
participants described the sensation initially as ‘’tingling’’ which increased in intensity over approximately 45 21 
minutes until a distinct ‘’stinging’’ or ‘’burning’’ pain was perceived (i.e. 50 VAS rating). Capsaicin responders 22 
were defined as participants who had established a stable pain VAS rating >50 for at least 45 minutes [28].  23 
Post-capsaicin EPP testing: Previous reports show that the mean area of punctate secondary mechanical 24 
hyperalgesia following topical application of 50 µl 1% capsaicin cream is 98.9 cm2 [8]. Secondary hyperalgesia 25 
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was then measured by testing EPP thresholds around the 4 points which covered an area of 64cm2 and avoided 1 
the neurogenic flare response area (Figure 1B).   2 
Virtual reality headset: An Oculus Rift VR headset connected to an MSI GT83 8RF laptop (Intel Core i7-8850H 3 
2.6GHz processor with NVIDIA GTX 1070 SLI 8GB graphics card) was used to display the passive virtual 4 
environment (Polar Obsession; National Geographic; Figure 1C). Participants were seated on a couch with knee 5 
extended to 180° and the Oculus Rift motion sensor provided position and orientation data regarding the 6 
subject’s head. The tracker’s sensor component was mounted on the Head-mounted Display (HMD), and its 7 
source component was mounted on an adjustable tripod placed in front of the couch. Sham VR stimulation 8 
consisted of playing the same video on a computer monitor screen.  9 
VR assessment: VR or sham VR stimulation was then given in 10-minute blocks, separated by 10-minute rest 10 
periods in a randomised manner (Figure 1D). Stimulation blocks were comprised of 5 minutes of VR or sham 11 
stimulation alone followed by 5 minutes of VR or sham + EPP testing. VAS scores were recorded at the end of 12 
each stimulation block. Each 10-minute rest period was comprised of a 5-minute wash out followed by 5 13 
minutes of post- VR or sham stimulation EPP testing. VAS scores were recorded at the end of each rest period.  14 
At the end of the study protocol, each participant was given an ice pack to cool any residual burning sensation 15 
and advised to repeat if any re-kindling occurred over 24 hours. 16 
Statistical analysis 17 
All data were initially entered into Microsoft Excel before being analysed for normality and statistical 18 
significance in GraphPad Prism (v8.0.1. GraphPad Software, Inc.). Percentage change in CPM effect was 19 
calculated as the conditioned PPT test stimulus minus the baseline PPT test stimulus divided by the baseline 20 
PPT test stimulus [47]. Therefore, more positive values indicated more efficient CPM.  EPP thresholds were 21 
averaged across all 4 points of the measurement map (i.e. proximal, distal, medial and lateral). Paired t-tests 22 
were used to analyse the changes in EPP threshold following application of capsaicin. One-way RM ANOVA with 23 
Holm-Sidak multiple comparison post hoc analysis was used to analyse the changes in raw EPP threshold or VAS 24 
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rating before, during and after either the real or sham VR stimulation. The difference between the percentage 1 
change in VAS rating from post-capsaicin to during VR/sham was analysed by paired test. One-way RM ANOVA 2 
with Holm-Sidak multiple comparison post hoc analysis was also used for comparing differences in the 3 
percentage change in EPP between pre- and post-capsaicin and between post-capsaicin and VR or sham VR 4 
conditions. Pearson correlation coefficient analysis was used to look for relationships between the VR-induced 5 
change in secondary hyperalgesia and CPM and the VR-induced change in pain perception and CPM. Pearson 6 
correlation analysis was also used to look for relationships between VR-induced changes in pain perception and 7 
VR-induced changes in secondary hyperalgesia. Statistical significance was set at p<0.05 and all data are 8 
presented as mean ± SEM in the figures and text, where appropriate.    9 
Results  10 
Capsaicin-induced ongoing pain and electrically evoked secondary hyperalgesia  11 
Topical application of capsaicin results in the development of an intense burning sensation and a neurogenic 12 
flare response (i.e. the primary zone; Figure 1C). A slight tingling sensation (VAS: 1.53 ± 0.2) began to appear 3 13 
minutes after the application of capsaicin cream (Figure 2A). The intensity of the sensation gradually increased, 14 
and an obvious burning sensation was achieved 36 minutes after the application of capsaicin (VAS: 52.47 ± 15 
1.07). Following the development of a stable ongoing pain response (i.e. p>0.05 between 45 minutes post 16 
capsaicin and 120 minutes post-capsaicin) there was a drop in EPP threshold in an area of capsaicin-induced 17 
secondary hyperalgesia (pre-EPP: 6.64 ± 0.14 mA vs. post-EPP: 5.33 ± 0.12 mA; P < 0.001; Figure 2B).  18 
VR was associated with an attenuation of ongoing pain perception  19 
Exposure to an immersive 3D VR environment caused a drop in VAS ratings below the defined pain threshold 20 
(post capsaicin VAS: 62.17 ± 2.07 versus during VR VAS: 47.67 ± 2.94; p<0.001; Figure 3A) which had returned 21 
to above pain threshold (i.e. > 50 VAS) when the VR headset was removed (post VR VAS: 54.40 ± 2.29; p<0.05). 22 
Sham VR was not associated with a drop in VAS rating during the stimulation (post capsaicin VAS: 62.17 ± 2.07 23 
versus during sham VR VAS: 57.39 ± 2.38; p > 0.05; Figure 3B) and there was no difference between during and 24 
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post sham VR stimulation (post sham VR: 56.32 ± 1.87; p > 0.05). A paired t-test showed a significant difference 1 
between the change in VAS rating during VR stimulation and the change in VAS rating during the sham VR 2 
stimulation (VR VAS: -23.08 ± 1.2% vs. sham VAS: -6.41 ± 1.18%; p < 0.01; Figure 3C).  3 
VR was associated with an attenuation of secondary hyperalgesia 4 
There was a significant increase in EPP threshold during VR stimulation (post capsaicin EPP threshold: 5.33 ± 5 
0.47 mA versus during VR EPP threshold: 6.78 ± 0.54 mA; p<0.001; Figure 4A) which was reversed following 6 
removal of the VR headset (post VR EPP threshold: 5.78 ± 0.51 mA; p<0.05). Sham VR stimulation was not 7 
associated with a change in EPP threshold during (5.87 ± 0.65 mA; p > 0.05; Figure 4B) or after (5.62 ± 0.55 mA; 8 
p > 0.05) the stimulation. Further analysis revealed there to be a significant difference in change in EPP threshold 9 
compared to post-capsaicin between VR and sham stimulation (VR: 3.05 ± 1.25% vs. sham EPP: -13.37 ± 1.42%; 10 
P < 0.05; Figure 4C).  11 
Relationships between baseline CPM responses and VR-induced analgesia  12 
Pressure pain thresholds were increased following the conditioning stimulus and therefore more efficient CPM 13 
is represented as a more positive value (Figure 5). There was no correlation between VR-induced decrease in 14 
VAS and CPM (r2 = 0.063, p > 0.05; Figure 5A). However, a significant correlation was found between VR-induced 15 
reduction in secondary hyperalgesia and CPM (r2 = 0.68, p<0.001; Figure 5B) in that higher levels of CPM 16 
measured at baseline (i.e. in the absence of capsaicin-induced sensitivity) were associated with a greater 17 
reduction in secondary hyperalgesia. There was no relationship between VR-induced changes in pain perception 18 
and VR-induced changes in secondary hyperalgesia (r2= 0.02; p=0.6).  19 
Discussion  20 
We have investigated the effects of distraction using an immersive VR environment on experimentally induced 21 
ongoing pain sensitivity and secondary hyperalgesia. Using the capsaicin model of ongoing afferent drive in 22 
healthy volunteers, we show an attenuation of ongoing pain ratings and electrically evoked secondary 23 
hyperalgesia during exposure to an immersive, polar VR environment. Interestingly, we found that the 24 
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magnitude of CPM measured at baseline was related to the VR-induced analgesic effect over secondary 1 
hyperalgesia but not the changes in pain ratings. These findings suggest that exposure to an immersive polar 2 
VR environment can be used to alter sensitised pain states and that CPM may be able to predict the efficacy of 3 
VR therapy in the treatment of chronic pain associated with hyperalgesia.  4 
It has previously been speculated that VR stimulation may provide a new approach for pain management during 5 
chronic pain conditions by distracting attention away from the ongoing pain [23; 39]. Our study provides new 6 
evidence that VR-stimulation can reduce capsaicin-induced ongoing pain perception. We also show novel 7 
mechanistic insight which supports the use of VR in patients with altered nociceptive processing and central 8 
sensitisation by showing that exposure to an immersive VR environment can increase pain thresholds in an area 9 
of spinally mediated enhanced pain sensitivity (i.e. secondary hyperalgesia).   10 
In the current study we used a passive VR design that created the impression of an immersive arctic scene 11 
during capsaicin-induced pain which is often described as ‘burning’. This is in line with a previous study which 12 
demonstrated, using an immersive cold environment, that is possible to reduce the perception of acute heat 13 
pain in healthy volunteers [15]. It is therefore possible that the counter-acting nature of cold VR environments 14 
has the ability to reduce the perception of an ongoing heat or burning pain. In the present study, we found that 15 
immersion within a virtual polar world could produce robust analgesic effects in the absence of any interactive 16 
elements which could make this approach favourable for use in patients with upper limb mobility issues. 17 
However, it has been previously suggested that the magnitude of VR induced analgesia is influenced by the 18 
addition of an interactive element [18; 41] as well as the quality of the visual display through the VR headset 19 
[17]. The majority of studies using acute pain or pain tolerance paradigms have adopted interactive designs 20 
with a view to optimise the shift in attention away from the pain and into the virtual world [5; 10; 12; 13; 15; 21 
16; 33]. It is therefore possible that the analgesic effects seen in this study could be further enhanced if an 22 
interactive element is used within the VR design.   23 
Previous research in chronic pain patients has focused on using VR involving the active navigation through 24 
fantasy landscapes and has been shown to reduce pain ratings in groups of patients with different aetiologies 25 
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[21; 22]. Despite showing clinically-relevant reductions in pain ratings, applying a single VR design to a mixed 1 
group of patients did not show any pain-relief at all in 10% of those recruited [22]. This could be attributed to a 2 
misalignment with the type of pain experienced by individual patients and the choice of VR environment. It is 3 
possible that specific VR environments could be more effective if aligned with the types of pain experienced, 4 
such as the use of a ‘snow world’ in burns patients [11]. In line with this, a case study demonstrated clinically-5 
relevant pain relief using an interactive cold environment in a treatment-resistant radiculopathy patient [35]. 6 
Future randomised controlled trials comparing the efficacy of different types of VR design in well-defined 7 
populations of chronic pain patients may therefore lead to more targeted use of VR therapy based on the types 8 
of pain experienced. 9 
We also show that during exposure to an immersive VR environment it is also possible to reduce capsaicin-10 
induced secondary hyperalgesia by measuring changes in electrically evoked pain thresholds. Previous research 11 
has shown that VR can be used to modulate acute pain thresholds in the absence of capsaicin-induced central 12 
sensitisation [9]. To our knowledge, our study is the first to show an analgesic effect over spinally mediated 13 
sensitised pain thresholds during exposure to a passive VR environment. Interestingly, we found no correlation 14 
between the VR-induced changes in ongoing pain perception and the VR-induced changes secondary 15 
hyperalgesia. This could either be explained through the different outcome measures obtained (i.e. pain scores 16 
versus pain thresholds) or that VR can exert analgesic effects on pain perception and secondary hyperalgesia 17 
via two separate mechanisms.  18 
Previous neuroimaging studies have shown that exposure to an immersive VR environment can activate a 19 
network of pain-related brain regions involved in top-down inhibitory control [14; 15] and that there is an 20 
increase in functional connectivity between the medial prefrontal cortex (mPFC) and spinally-projecting centres 21 
in the midbrain and brainstem during distraction-based analgesia [4; 29; 36; 40].  It is therefore possible that 22 
VR can engage similar top-down analgesic pathways involved in the descending modulation of spinal cord 23 
nociceptive processing in a manner akin to that seen during non-invasive brain stimulation [19; 20; 31]. The 24 
analgesic effects on capsaicin-induced ongoing pain ratings could be due to activation of a cortico-cortical 25 
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analgesic pathway associated with emotion and memories as well as auditory or visual stimuli, which is distinct 1 
from the top-down activation of the descending pain modulatory network [7; 43].  2 
It has been previously shown that measuring CPM at baseline can be used to identify individuals likely to benefit 3 
from VR during an acute pain tolerance test [3]. The present study extends these findings to show that CPM can 4 
be also be used to identify those likely to show a greater reduction in experimentally induced secondary 5 
hyperalgesia. It is becoming increasingly clear that CPM is not just dependent on activation of a spino-bulbo-6 
spinal loop mechanism first proposed in rodents [26; 27], but is also open to interaction with psychological and 7 
cognitive factors [6; 34]. It is therefore possible that the association observed in the present study is due to 8 
distraction playing a role in both the CPM effects as well as the VR-induced changes in secondary hyperalgesia. 9 
This is supported through recent neuroimaging studies which have shown that both CPM and VR are associated 10 
with activation of the anterior cingulate cortex (ACC) [15; 32]; an area of the brain closely linked with distraction 11 
analgesia which has been shown to be involved in top-down pain control [2; 14-16]. CPM has been previously 12 
shown to predict the response to duloxetine in diabetic neuropathy patients, by mimicking the action of 13 
descending monoaminergic inhibitory pathways [48]. The association seen between CPM and VR-induced 14 
changes in secondary hyperalgesia suggest that VR may exert a top-down influence on similar spinally-15 
projecting descending control pathways [43; 44]. Another possible explanation for the observed relationship 16 
between CPM and VR-induced changes in secondary hyperalgesia is that they are both measuring changes in 17 
pain threshold. However, as we were testing two separate modalities in these paradigms (i.e. PPT and EPP) it is 18 
more likely that the CPM response and the VR-induced changes in secondary hyperalgesia share similar top-19 
down mechanisms. To confirm this, further psychophysical and neuroimaging research is required to show 20 
whether exposure to VR can modulate the CPM response and activate common pain-related brain and 21 
brainstem regions.    22 
This proof-of-concept study is the first to show evidence that VR stimulation can modulate altered nociceptive 23 
processing associated with the development of chronic pain states. However, there are a few limitations with 24 
our study that should be addressed in larger randomised controlled trials. We used a within-subject design to 25 
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test the effects of short periods of VR or sham VR stimulation on established pain sensitivity. We found the 1 
effects to be transient and dependent on the presence of the VR environment. Future studies adopting a cross-2 
over design with participants randomly assigned to either real or sham VR conditions will allow longer 3 
stimulation times and measurement of the time course of the analgesic effects following cessation of the VR 4 
environment. It would also be of interest to investigate the effects of VR on other measures of central 5 
sensitisation such as dynamic mechanical allodynia or whether it is possible to reduce areas of punctate 6 
mechanical secondary hyperalgesia.  7 
In summary, the study presented here demonstrates the first evidence that a passive VR design can reduce 8 
both ongoing pain perception and secondary hyperalgesia during an experimentally induced sensitised pain 9 
state. We show that exposure to a cold immersive VR environment may be a promising new analgesic therapy 10 
for use in chronic pain patients by providing a novel non-pharmacological approach to alleviate the severity of 11 
ongoing pain and associated spinal cord excitability. It may also be possible to use CPM to guide future 12 
phenotype-stratified trials with VR in the treatment of chronic pain.  13 
Acknowledgements 14 
We would like to thank Imperial College London for funding this study and all participants for taking part. We 15 
would also like to thank Dr Helen Laycock for advice on mapping secondary hyperalgesia.   16 
Conflict of interest statement 17 
The authors report no conflicts of interest. 18 
Figure legends  19 
Figure 1. Measuring capsaicin-induced secondary hyperalgesia and experimental protocol. A) secondary 20 
hyperalgesia measurement map. Central black zone indicates position of topical application of 50 µl 1% 21 
capsaicin cream. Dark grey zone indicates the region of the neurogenic flare response (i.e. primary hyperalgesia 22 
zone). EPP thresholds are determined across proximal (P), distal (D), medial (M) and lateral (L) points in the 23 
secondary hyperalgesia zone. B) Experimental protocol. C) Image showing the development of a neurogenic 24 
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flare response and placement of the 4 modified Ag/AgCl electrodes for measurement of secondary 1 
hyperalgesia. D) Screen capture from the Polar Obsession VR environment.  2 
Figure 2. Development of capsaicin-induced ongoing pain and secondary hyperalgesia. A) Time course for the 3 
development of pain sensation following topical application of 50µl 1% capsaicin cream. The intensity of 4 
sensation increased until pain threshold was reached at 36 minutes (i.e. dotted line; 50 VAS). B) There was a 5 
significant drop in EPP threshold in an area of capsaicin-induced secondary hyperalgesia. Data are expressed as 6 
mean ± SEM; *** - P<0.001. n = 15.  7 
Figure 3. Transient changes in ongoing pain perception following VR stimulation. Changes in pain VAS ratings 8 
before, during and after A) real and B) sham VR stimulation. C) Comparison between the changes in pain rating 9 
during either real or sham VR stimulation. Data are expressed as mean ± SEM; * - P<0.05, ** - P<0.01, *** - 10 
P<0.001. n = 15. 11 
Figure 4. Transient changes in secondary hyperalgesia following VR stimulation. Changes in EPP threshold 12 
before, during and after A) real and B) sham VR stimulation. C) Comparison between changes in EPP threshold 13 
between real and sham VR with respect to sensitised post-capsaicin EPP thresholds. Data are expressed as mean 14 
± SEM; * - P<0.05, *** - P<0.001. n = 15. 15 
Figure 5. Baseline CPM correlated with VR-induced changes in secondary hyperalgesia but not VR-induced 16 
changes in pain perception. A) no relationship between the VR-induced reduction in ongoing pain perception 17 
and levels of CPM. B) Reduction in secondary hyperalgesia is related to baseline CPM levels. n = 15.  18 
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